

VERNIERI CLAUDIO

Address:

Telephone:

E-mail: claudio.vernieri@unimi.it; claudio.vernieri@istitutotumori.mi.it;
claudio.vernieri@ifom.eu

Date/place of birth:

Fiscal code:

EDUCATION AND TRAINING

- December 2019: Board Certification in Medical Oncology (score: 70/70 cum laude) from the University of Milan. Title of the thesis: "Safety, feasibility and biological effects of cyclic fasting-mimicking diet (FMD) in cancer patients".
- December 2014 – December 2019: Residency in Medical Oncology at Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (Milan, Italy).
- December 2014 – December 2019: Joint Post-Doc at Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (Milan, Italy) and IFOM ETS, the AIRC Institute of Molecular Oncology (Milan, Italy).
- April 2014 – November 2014: post-doc fellow at IFOM (Milan, Italy).
- January 2010 – March 2014: PhD in Molecular Medicine at the SEMM (European School of Molecular Oncology) in IFOM (Milan, Italy). Title of the thesis: "Cdk1 kinase counteracts PP2A^{Cdc55} phosphatase to induce APC/C phosphorylation and adaptation to the Spindle Assembly Checkpoint (SAC) in budding yeast".
- July 2009 – December 2009: Resident in Clinical Radiotherapy at Policlinico Universitario "Federico II" (Naples, Italy).
- July 2008: M.D. degree in Medicine received from the University Federico II of Naples, Italy, with the final mark of 110/110 cum laude and honors by the Degree Committee (Naples, Italy). Title of the thesis: "Study of the effects induced by the association of a selective inhibitor of farnesyltransferase (tipifarnib) with ionizing radiations in cell lines from squamocellular neoplasms (Kb, Cal-27)".
- September 2002 – July 2008: student of Medicine and Surgery at the University Federico II of Naples.

RESEARCH AND PROFESSIONAL EXPERIENCE

October 2024 – present

Associate Professor at the University of Milan, Milan, Italy

September 2024 – present

Member of the Scientific Committee of Psiconcologia.net platform

December 2023–September 2024

Assistant Professor at the University of Milan, Milan, Italy

April 2023– present

Elected Member of the Scientific Direction Advisory Committee of IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy

November 2022– present

Elected Member of the Scientific Committee (CTS) of Accademia "Umberto Veronesi"

January 2020 – present

Principal Investigator at IFOM ETS, the AIRC Institute of Molecular Oncology, as director of the “Metabolic Reprogramming in Solid Tumors” program

January 2020 – present

Medical Oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori, responsible for the design, coordination and conduction of clinical trials focused on breast cancer and cancer metabolism (NCT03340935, NCT03454282, NCT03709147), including studies in the role of Principal Investigator (NCT04248998 and NCT04001725).

January 2020 – present

Member of the Faculty board for the PhD program at the SEMM (European School of Molecular Medicine)

January 2019 – December 2022

Elected Member of the Scientific Directorate of Fondazione IRCCS Istituto Nazionale dei Tumori di Milano.

February 2018 – present

Member of the Cancer Core Europe (CCE) Network and local responsible for CCE Clinical Trials and translational research activities (Basket-of-Basket Clinical Trial; DART project funded by H2020).

December 2014 – December 2019

Resident in Medical Oncology at the Medical Oncology Department of Fondazione IRCCS Istituto Nazionale Tumori di Milano under the supervision of Prof. Filippo de Braud. I was involved in: 1) designing and conducting independent clinical trials to target cancer metabolism, including prospective studies on calorie restriction and metformin (NCT03340935, NCT03454282, NCT03709147, NCT04248998, NCT04001725); 2) clinical management of patients with limited-stage and advanced breast cancer, including treatment with chemotherapy, endocrine therapy and molecular targeted treatments; 3) participation in sponsored clinical trials in breast cancer patients, including studies with immunotherapy, cyclin-dependent kinase 4/6 inhibitors, PI3K inhibitors and new immune conjugates; 4) supervision, with the role of mentor and thesis co-advisor, of students in Medicine in projects focused on the study of lipid metabolism in HER2+ BC and pancreatic neuroendocrine tumors (pNETs); 5) coordination of clinical and translational research activities of residents in Medical Oncology at Fondazione IRCCS Istituto Nazionale dei Tumori di Milano; 6) collaboration or conduction of translational research project focused on breast cancer, lung cancer, renal cancer and pNETs.

December 2014 – December 2019

Joint IFOM-INT post-Doc, working on research projects focused on cancer metabolism and tumor resistance to taxanes, in collaboration with the groups directed by Prof. Marco Foiani, Prof. Valter Longo, Dr. Andrea Ciliberto and Dr. Stefano Casola.

April 2014 – November 2014

Post-doctoral fellowship in the “Quantitative Biology of Cell Division” Laboratory directed by Dr. Andrea Ciliberto.

January 2010 – March 2014

PhD student at the SEMM (European School of Molecular Medicine) at the F.I.R.C. Institute of Molecular Oncology (IFOM) in Milan, under the supervision of Dr. Andrea Ciliberto.

Main project: The balance between APC subunit phosphorylation by Cdk1/CycB, and dephosphorylation by PP2A^{Cdc55} in the adaptation to the spindle assembly checkpoint (SAC) in budding yeast cells. **Secondary projects:** collaborations with Prof. Andrea Musacchio's group (IEO, Milan) to study the role of Aurora B in the SAC of mammalian cells and with Prof. Ruggero Pardi in San Raffaele (Milan, Italy) on models of cellular migration in the Medaka fish model.

September 2006 – July 2008

Experimental Master degree thesis on the synergistic effects of the Farnesyl-transferase inhibitor Tipifarnib and ionizing radiations on head and neck cancer cell lines.

SKILLS AND COMPETENCES

- Leadership experience: Group leader at IFOM (director of an independent research program currently involving 9 scientists: Dr. Giulia Salvadori, Dr. Mattia Rediti, Dr. Francesca Ligorio, Dr. Marzia Santamaria, Dr. Beatrice Cantarelli, Dr. Maria Elena Steidl, Dr. Keagile Bati, Dr. Giacomo Mazzoli, Dr. Leonardo Provenzano) and leader at INT (reponsible for clinical research programs involving 8 medical oncologists and nutritionists: Dr. Francesca Ligorio, Dr. Giovanna Armani, Dr. Leonardo Provenzano, Dr. Flavia Jacobs, Dr. Giuseppe Fotia, Dr. Giacomo Mazzoli, Dr. Lucrezia Zanenga, Dr. Silvia Paderno).
- Expertise in designing, conducting and coordinating clinical trials in patients with limited-stage and advanced cancers (Clinicaltrials.gov Identifiers: NCT03340935, NCT03454282, NCT03709147, NCT04248998, NCT04001725; NCT06805812).
- Statistics, biostatistics, survival analysis, multivariable analysis, propensity score analysis (R, MATLAB); image processing (Adobe Photoshop, ImageJ).
- Molecular Biology (DNA, RNA and protein techniques), Biochemistry (western blot analysis, immunoprecipitation assays), Yeast Genetics, Cell Biology (Cell culture, viability assays), Flow Cytometry, Microscopy (Bright field, IF/ICC, live cell microscopy on yeast and mammalian cells), Softwares (Programming in Python and MATLAB; automated image analysis (vHCS Scan, CellProfiler).
- Expertise in conducting bioinformatic analyses of transcriptomic, proteomic and metabolomic data from cell lines, mouse samples and human samples.
- Computational approaches to biological problems through mathematical modeling and analysis (ordinary differential equations; MATLAB and XPP/XPPAUT).
- Clinical independence in managing cancer patients in their global cure process (5-year clinical experience as a Resident in Medical Oncology).
- Clinical independence as a general medical doctor (2-year experience as a medical volunteer assisting patients with basic medical needs at Naga, Milan, Italy).
- Mentorship experience: Mentor of students in Biology (Dr. Valentina Francia) and Medicine (Dr. Pietro Indelicato, Dr. Marta Rossi, Dr. Luca Zambelli). Mentor of PhD students in Nutrition Sciences (Dr. Marzia Sucameli). Mentor of Residents in Medical Oncology at Fondazione IRCCS Istituto Nazionale dei Tumori (Dr. Francesca Ligorio; Dr. Riccardo Lobefaro; Dr. Emma Zattarin; Dr. Giorgia Peverelli; Dr. Leonardo Provenzano; Dr. Caterina Sposetti; Dr. Giuseppe Fotia; Dr. Giacomo Mazzoli). Mentor of PhD students in Molecular Oncology at IFOM (Dr. Beatrice Cantarelli, UK PhD; Dr. Marzia Santamaria, UK PhD; Dr. Francesca Ligorio, UK PhD; Dr. Emanuele Frigo; Dr. Giacomo Mazzoli; Dr. Keagile Bati). Mentor of Post-Doc in Molecular Oncology (Dr. Giulia Salvadori; Dr. Mattia Pavani; Dr. Mattia Rediti; Dr. Maria Elena Steidl).
- Internal supervisor of PhD students: Riccardo Valzelli (mentor: Saverio Minucci at IEO, Istituto Europeo di Oncologia); Bianca Barzaghi (mentor: Giuseppe Testa at IEO, Istituto Europeo di Oncologia)
- Internal examiner of PhD students: Giulia Salvadori (2019) from Valter Longo's group (IFOM)

GRANTS AND FELLOWSHIPS

- **November 2024: AIRC IG (Investigator grant)** for a project entitled "Targeted amino acid supplementation plus fasting as a novel anticancer strategy against the "big

killers”: AMINOFAST”. PI: C. Vernieri. Project code: IG 2024 ID 30499. 1.784.000 euro for 5 years

- **September 2023: ERC Starting Grant** for a project entitled “METABALANCANCER – Setting the optimal balance between metabolite supplementation and deprivation in cancer therapy”. PI: C. Vernieri. Project code: 101117893. 1.499.250 euro for 5 years
- **October 2022:** internal grant of the Scientific Directorate of Fondazione IRCCS Istituto Nazionale dei Tumori for a project entitled “Leucine supplementation plus fasting-mimicking diet to improve the efficacy of chemoimmunotherapy in triple-negative breast cancer”. PI: C. Vernieri; 530.000,00 euros for 3 years
- **June 2020: H2020 Grant (H2020-SC1-2020-Lump-Sum-RTD)** within the Cancer Core Europe Consortium for a project entitled “CCE_DART”. PI of Work Package 10: Claudio Vernieri. Budget allocated for WP10: 116.264,50 euros for 5 years.
- **November 2019: My First AIRC Grant (MFAG)** for a project entitled “Exploiting inducible metabolic vulnerabilities to improve chemotherapy efficacy in triple negative breast cancer”. PI: C. Vernieri. Project Code: 22977 (499.118,4 euros for 5 years).
- **June 2019:** internal grant of the Scientific Directorate of Fondazione IRCCS Istituto Nazionale dei Tumori for studies focused on triple-negative breast cancer metabolism (205.000,00 euros in 3 years). PI: C. Vernieri.
- **November 2014:** one-year AIRC post-doctoral fellowship. Title of the project: “*Uncovering the role of Cdc20 levels in the heterogeneity of times of adaptation to the Spindle Assembly Checkpoint*”.
- **December 2014:** five-year fellowship from the University of Milan as a resident in Medical Oncology.
- **January 2010:** full Doctorial Scholarship Awarded by the University of Milan through competitive admission to the research doctorate course denominated “PhD in Molecular Medicine”.
- **July 2009:** five-year fellowship from the University Federico II of Naples as a resident in Radiotherapy.

COLLABORATOR IN OTHER GRANTS

- AIRC IG: PI Maria Vittoria Dieci (2022-2027). Title of the project: “Immunometabolic profile to personalize immunotherapy for patients with triple negative breast cancer”. Collaborator in the conduction of translational immunometabolic evaluations in tumor specimens and plasma samples from patients enrolled in the A-BRAVE trial.
- AIRC IG: PI Giancarlo Pruneri (2022-2027). Title of the project: “UNDERSTAND – Untavelling tumor resistance mechanisms in HR+ aDvanced bReaST cANcer undergoing CDK4/6 inhibitors therapy”. Collaborator of the clinical part of the study, and responsible for preclinical experiments (Task 4) to identify metabolic mechanisms of HR+/HER2- BC cell resistance to CDK4/6 inhibitors.
- AIRC IG: PI Tiziana Triulzi (2021-2025). Title of the project: “New potential therapeutic targets for triple negative breast cancer patients from the study of tumor-adipocyte crosstalk”.
- AIRC IG: PI Paolo Maiuri (2021-2025). Title of the project: “Mechano-perturbation of the cell nucleus in tumor progression”.
- AIRC IG: PI Serenella M. Pupa (2010-2024). Title of the Project: “Targeting fatty acid uptake pathway to revert resistance to anti-HER2 agents in HER2-positive breast cancer”.

- AIRC IG: PI Andrea Ciliberto (2018-2023). Title of the Project: “Dissecting the role of Cdc20 in the resistance to antimetabolites: from evolution experiments to clinical testing”.
- AIRC IG: PI Marina C. Garassino (2017-2021). Title of the Project: “Exploiting LKB1 vulnerability by selective metabolic treatments in advanced Non-Small Cell Lung Cancer”
- AIRC IG: PI Licia Rivoltini (2017-2022). Title of the Project: “Dietary intervention and physical exercise as modulators of cancer immunity in clinical setting”.
- Bando per la valorizzazione della Ricerca Istituzionale 2017 della Fondazione IRCCS Istituto Nazionale dei Tumori. PI: Filippo de Braud (2018-2020). Title of the Project: “Metabolic and immunomodulatory effects of high-dose glucocorticoids plus/minus metformin in metastatic cancer patients”
- ERANET TRANSCAN-2 (Joint Translational Call for Proposals 2015). PI: Filippo de Braud (2018-2020). Title of the Project: “Impact of Dietary Intervention on tumour immunity”

AWARDS

- **October 2024:** University of Padua Award for Advances in Breast Cancer 2024 Awardee lecture entitled “Boosting Academic Research to Meet the Unmet Needs in Breast Cancer Therapy”.
- **March 2023:** MERIT AWARD 2023 for Medicine by the Association “Insieme con Merito” (Milan, Italy)
- **January 2022:** Award by the EACR (European Association for Cancer Research) for the manuscript entitled “Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in cancer patients”, which was included in the list of “*The EACR’s Top 10 Cancer Research Publications*”.
- **May 2019:** 2018 Young Researcher Award of the Fondazione IRCCS Istituto Nazionale dei Tumori for results obtained in the field of Translational Cancer Research.
- **February 2018:** Conquer Cancer Foundation Merit Award for a work entitled: “*Prognostic and predictive role of Fumarate Hydratase in metastatic clear cell Renal Cell Carcinoma*” presented at the 2018 Genitourinary Cancers Symposium (ASCO GU 2018).

PATENTS

Co-inventor of “Preparazione alimentare a basso contenuto calorico per l'alimentazione di pazienti affetti da neoplasie”. Italian Patent released. First deposited Italian patent n. 102019000009954 (24th June 2019). Extension PCT WO 2020/261131 24th June 2020. European Patent n. 20740399 (pending). Canadian patent n. 2,144,217 (pending). USA (pending).

Co-inventor of “Preparazione alimentare per l'alimentazione di pazienti oncologici avente un ridotto apporto calorico”. International patent request n. PCT/IT2020/000083. Deposited on 17th Dec 2020 (pending)

MEMBERSHIPS OF SCIENTIFIC SOCIETIES

- ASCO: American Society of Clinical Oncology
- ESMO: European Society of Medical Oncology
- AIOM: Associazione Italiana di Oncologia medica
- CCE: Cancer Core Europe

REVIEWER FOR THE FOLLOWING SCIENTIFIC JOURNALS:

- The Lancet Oncology
- Annals of Oncology
- Cell Reports Medicine
- Nature Communications
- Journal of Thoracic Oncology
- Journal for ImmunoTherapy of Cancer
- Cancer Communications
- Aging Cell
- Cancer Research
- European Journal of Cancer
- Oncogene
- International Journal of Cancer
- Trends in Endocrinology and Metabolism
- NPJ Breast Cancer
- Cancers (Basel)
- Cancer Treatment Reviews
- Scientific Reports
- The Breast
- Oncotarget
- Critical Reviews in Oncology/Hematology
- Therapeutic Advances in Medical Oncology
- Translational Cancer Research
- Annals of Translational Medicine
- Cancer Management and Research
- Tumori Journal

REVIEWER OF GRANT APPLICATIONS

- **March 2022:** Reviewer of a preclinical grant application for the Swiss Cancer Research and Swiss Cancer League
- **February 2022:** Reviewer of a clinical grant application for the Swiss Cancer Research and Swiss Cancer League
- **September 2021:** Reviewer of grant application for the KWF Kankerbestrijding (Dutch Cancer Society)
- **December 2020:** Reviewer of the “Bando per la valorizzazione della ricerca istituzionale in ambito oncologico 2020” for Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia

PUBLICATIONS

- 1 Blondeaux E, Delucchi V, Mariamidze E, Bernstein-Molho R, Frank S, Ferrari A, Linn S, Jeong Kim H, Agostinetto E, Paluch-Shimon S, Cortesi L, Di Meglio A, Balmana J, Yerushalmi R, Rodriguez-Wallberg KA, Renaud T, Cui W, Moore HCF, Wong SM, Pogoda K, Lustberg M, Phillips KA, Han S, Puglisi F, **Vernieri C**, Bajpai J, Sonnenblick A, Rousset-Jablonski C, De Marchis L, De Giorgi U, Bianchini G, Teixeira L, Duhoux FP, Villarreal-Garza C, Sini V, Fruscio R, Del Mastro L, Demeestere I, Azim HA Jr, Peccatori FA, Partridge AH, Lambertini M. *J Natl Cancer Inst* 2025. PMID: 40623009
- 2 Blondeaux E, Sonnenblick A, Agostinetto E, Bas R, Kim HJ, Franzoi MA, Bernstein-Molho R, Linn S, Kwong A, Pogoda K, Balmana J, Smeets A, Bajpai J, Moore HCF,

- Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Mando P, Lee JE, Fruscio R, Cui W, Wong SM, **Vernieri C**, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Guven DC, Lee M, Villarreal-Garza C, Hwang SE, De Marchis L, Puglisi F, Kemp Z, Meireles PA, Parokonnaya A, Werutsky G, Okano M, Azim HA Jr, Mati K, Rosenberg S, Gelber R, Boni L, Lambertini M. Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study. *Lancet Oncol* 2025. PMID: 40347973.
- 3 Magaton IM, Blondeaux E, Hamy AS, Linn S, Bernstein-Molho R, Peccatori FA, Ferrari A, Carrasco E, Paluch-Shimon S, Agostinetto E, Venturelli M, Luis IMV, Rodriguez-Wallberg KA, Kim HJ, Sorouri K, Renaud T, Moore HCF, Cui W, Bajpa J, Rousset-Jablonski C, De Marchis L, Yerushalmi R, Wong SM, Han S, Phillips KA, Pogoda K, Puglisi F, Chirco A, Duhoux FP, Meattini I, Villarreal-Garza C, **Vernieri C**, Bruzzzone M, Demeestere I, Azim HA Jr, Partridge AH, Lambertini M. Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study. *Eur J Cancer* 2025. PMID: 40300260
 - 4 Nichetti F, Brambilla M, Duca M, Piccolo A, Miliziano D, Cavalli C, Marra F, Ambrosini P, Zanella C, **Vernieri C**, Lorenzini D, Colombo E, Damian S, Baili P, Proto C, Busico A, Conca E, Capone I, Manoukian S, Tamborini E, Perrone F, Niger M, Vingiani A, Agnelli L, de Braud F, Pruner G. Real-World Outcomes of Molecular Tumor Board Treatment Recommendations. *JCO Precis Oncol* 2025. PMID: 40499091
 - 5 Scafetta R, Donato M, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Troiano R, Foderaro S, Ricozzi V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, Botticelli A, Scagnoli S, Pisegna S, Criscitiello C, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Rossino MG, Domati F, Piombino C, Di Lisa FS, Filomeno L, Arcuri T, Puce F, Riva F, Palleschi M, Sirico M, Piras M, Stucci LS, De Lisi D, Orsaria P, Ippolito E, Ramella S, Visani L, Bertini N, Bonaparte I, Gori S, Rossi L, Meattini I, Tagliaferri B, Caffo O, Portarena I, Irelli A, Cretella E, Porta C, Bianchini G, Fabbri A, De Giorgi U, Vici P, Toss A, Garrone O, De Laurentiis M, Villa F, Berardi R, Minelli M, **Vernieri C**, Curigliano G, Vincenzi B, Tonini G, Santini D, Pantano F. Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors. *Breast* 2025. PMID: 40424680
 - 6 De Micheli V, Agnelli L, Conca E, Rabsiun Aramburu VL, Baggi A, Vingiani A, Duca M, Perrone F, Tamborini E, Piccolo A, Lorenzini D, Busico A, Capone I, Niger M, Proto C, **Vernieri C**, Manoukian S, Gancitano G, Ferrario M, Franzini JM, De Braud F, Pruner G, Jommi C. Impact of comprehensive genomic profiling and molecular tumour board on costs and access to tailored therapies: real-world observational study. *BMJ Open* 2025. PMID: 40379307
 - 7 Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Miliziano D, Menichetti A, Ligorio F, Zurlo C, Griguolo G, Berton Giachetti PP, Faso V, Corti C, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, Criscitiello C, Guarneri V, Pruner G, Mariani L, **Vernieri C**; Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+/HER2- BC patients: results from the multicenter PALMARES-2 study. *Ann Oncol* 2025. PMID: 40204155
 - 8 De Placido P, Di Rienzo R, Pietroluongo E, Martinelli C, Tafuro M, Formisano P, D'Esposito V, Poggio FB, Ruelle T, Cardinali B, Di Lauro V, Buono G, Caputo R, Buonaiuto R, Caltavitturo A, Rocco P, Porciello G, De Laurentiis M, Del Mastro L, **Vernieri C**, Veneziani BM, Bianco R, Crispo A, De Angelis C, Arpino G, Giuliano M. Insights on the association of anthropometric and metabolic variables with tumor features

- and genomic risk in luminal early breast cancer: Results of a multicentric prospective study. *Eur J Cancer* 2025. PMID: 40220739
- 9 Lambertini M, Blondeaux E, Tomasello LM, Agostinetti E, Hamy AS, Kim HJ, Franzoi MA, Bernstein-Molho R, Hilbers F, Pogoda K, Wildiers H, Bajpai J, Ignatiadis M, Moore HCF, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Criscitiello C, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, **Vernieri C**, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Rodriguez-Wallberg KA, Duhoux FP, Livraghi L, Bruzzone M, Boni L, Balmaña J. Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status. *J Clin Oncol* 2025. PMID: 39993249.
 - 10 Berton Giachetti PPM, Morganti S, Gandini S, Giudici F, Marra A, Nicolò E, Zattarin E, Corti C, Boldrini L, Verrazzo A, Sposetti C, Razeti MG, Carnevale Schianca A, Scafetta R, Taurelli Salimbeni B, Esposito A, Zagami P, Trapani D, Malagutti B, Caputo R, **Vernieri C**, Munzone E, Scagnoli S, Botticelli A, Lambertini M, Giuliano M, De Laurentiis M, Viale G, Bianchini G, Curigliano G, De Angelis C, Criscitiello C. Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. *JAMA Netw Open* 2025. PMID: 39982725.
 - 11 Ligorio F, Vingiani A, Torelli A, Sposetti C, Druifuca L, Iannelli F, Zanenga L, Depretto C, Folli S, Scaperrotta G, Capri G, Bianchi GV, Ferraris C, Martelli G, Maugeri I, Provenzano L, Nichetti F, Agnelli L, Lobefaro R, Fucà G, Fotia G, Mariani L, Morelli D, Ladisa V, De Santis MC, Lozza L, Trecate G, Belfiore A, Brich S, Bertolotti A, Lorenzini D, Ficchi A, Martinetti A, Sottotetti A, Arata A, Corsetto PA, Sorrentino L, Rediti M, Salvadori G, Minucci S, Foiani M, Apolone G, Pagani M, Pruneri G, de Braud F, **Vernieri C***. Early downmodulation of tumour glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients. *Cell Metab* 2025. PMID: 39694040
 - 12 Miglietta F, Collesei A, **Vernieri C**, Giarratano T, Giorgi CA, Girardi F, Griguolo G, Cacciatore M, Botticelli A, Vingiani A, Fotia G, Piacentini F, Massa D, Zanghì F, Marino M, Pruneri G, Fassan M, Dei Tos AP, Dieci MV, Guarneri V. Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study. *ESMO Open* 2025. PMID: 39705838
 - 13 Castagnoli L, Franceschini A, Cancila V, Dugo M, Bigliardi M, Chiodoni C, Toneguzzo P, Regondi V, Corsetto PA, Pietrantonio F, Mazzucchelli S, Corsi F, Belfiore A, Vingiani A, Pruneri G, Ligorio F, Colombo MP, Tagliabue E, Tripodo C, **Vernieri C**, Triulzi T, Pupa SM. CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer. *J Exp Clin Cancer Res* 2025. PMID: 39833955
 - 14 Fabi A, Rossi A, Caputo R, Pisegna S, Scagnoli S, Pantano F, D'Auria G, Fedele P, Fabbri A, **Vernieri C**, Palleschi M, Carbognin L, Ferretti G, Di Monte E, Paris I, Pavese F, Garrone O, Franco A, De Laurentiis M, Franceschini G, Scambia G, Giannarelli D, Masetti R, Botticelli A. Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan. *NPJ Precis Oncol* 2025. PMID: 39843642.
 - 15 Massa D, **Vernieri C**, Nicolò L, Criscitiello C, Boissière-Michot F, Guiu S, Bobrie A, Griguolo G, Miglietta F, Vingiani A, Lobefaro R, Taurelli Salimbeni B, Pinato C, Schiavi F, Brich S, Pescia C, Fusco N, Pruneri G, Fassan M, Curigliano G, Guarneri V, Jacot W, Dieci MV. Immune and Gene-expression Profiling in Estrogen Receptor Low and Negative Early Breast Cancer. *J Natl Cancer Inst.* 2024. PMID: 39083015
 - 16 Koppold DA, Breinlinger C, Hanslian E, Kessler C, Cramer H, Khokhar AR, Peterson CM, Tinsley G, **Vernieri C**, et al. International consensus on fasting terminology. *Cell Metab* 2024. PMID: 39059384
 - 17 Agostinetti E, Bruzzone M, Hamy AS, Kim HJ, Chiodi C, Bernstein-Molho R, Linn S, Pogoda K, Carrasco E, Derouane F, Bajpai J, Nader-Marta G, Lopetegui-Lia N, Partridge

- AH, Cortesi L, Rousset-Jablonski C, Giugliano F, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, **Vernieri C**, et al. Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology. *ESMO Open* 2024. PMID: 39288653
- 18 **Vernieri C***, Ligorio F, Tripathy D, Longo VD. Cyclic fasting-mimicking diet in cancer treatment: Preclinical and clinical evidence. *Cell Metab* 2024. PMID: 39059383
 - 19 Arecco L, Bruzzzone M, Bas R, Kim HJ, Di Meglio A, Bernstein-Molho R, Hilbers FS, Pogoda K, Carrasco E, Punie K, Bajpai J, Agostinetto E, Lopetegui-Lia N, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Curigliano G, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, **Vernieri C**, Couch FJ, Dieci MV, Matikas A, Rozenblit M, Aguilar-Y Méndez D, De Marchis L, Puglisi F, Fabi A, Graff SL, Witzel I, Rodriguez Hernandez A, Fontana A, Pesce R, Duchnowska R, Pais HL, Sini V, Sokolović E, de Azambuja E, Ceppi M, Blondeaux E, Lambertini M. Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers. *Ann Oncol* 2024. PMID: 38908482
 - 20 Sorrentino L, Daveri E, Belli F, Vigorito R, Battaglia L, Sabella G, Patti F, Randon G, Pietrantonio F, **Vernieri C**, Scaramuzza D, Villa S, Milione M, Gronchi A, Cosimelli M, Guaglio M. Management of patients with locally recurrent rectal cancer with a previous history of distant metastases: retrospective cohort study. *BJS Open* 2024. PMID: 38869237
 - 21 Schettini F, Blondeaux E, Molinelli C, Bas R, Kim HJ, Di Meglio A, Bernstein Molho R, Linn SC, Pogoda K, Carrasco E, Punie K, Agostinetto E, Lopetegui-Lia N, Phillips KA, Toss A, Rousset-Jablonski C, Acheritogaray M, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, **Vernieri C**, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Vasconcelos de Matos L, Mariño M, Teixeira L, Graffeo R, Rognone A, Chirco A, Antone N, Abdou Y, Marhold M, Božović-Spasojević I, Cortés Salgado A, Carmisciano L, Bruzzzone M, Curigliano G, Prat A, Lambertini M. Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study. *Cancer* 2024. PMID: 38752572
 - 22 Raucci F, **Vernieri C***, Di Tano M, Ligorio F, Blaževitš O, Lazzeri S, Shmahala A, Fragale G, Salvadori G, Varano G, Casola S, Buono R, Visco E, de Braud F, Longo VD. Cyclic Fasting-Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia. *Cancer Res.* 2024. PMID: 38241703
 - 23 Zattarin E, Mariani L, Menichetti A, Leporati R, Provenzano L, Ligorio F, Fucà G, Lobefaro R, Lalli L, Vingiani A, Nichetti F, Griguolo G, Sirico M, Bernocchi O, Marra A, Corti C, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Presti D, Sposetti C, Giorgi C.A., Guarnieri V, Pedersini R, Losurdo A, Generali D, Curigliano G, Prunerì G, de Braud F, Dieci M.V. and **Vernieri C***. Peripheral blood lymphocytes predict clinical outcomes in Hormone Receptor-positive HER2-negative advanced Breast Cancer patients treated with CDK4/6 inhibitors. *Ther Adv Med Oncol* 2023. PMID: 38130467
 - 24 Pusceddu S, Corti F, Prinzi N, Nichetti F, Ljevar S, Busico A, Cascella T, Leporati R, Oldani S, Pircher CC, Coppa J, Resi V, Milione M, Maccauro M, Miceli R, Tamborini E, Perrone F, Spreafico C, Niger M, Morano F, Pietrantonio F, Seregni E, Mariani L, Mazzaferro V, Di Liberti G, Fucà G, de Braud F, **Vernieri C***. Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2. *J Hematol Oncol.* 2023. PMID: 38098114
 - 25 Lambertini M, Blondeaux E, Agostinetto E, Hamy AS, Kim HJ, Di Meglio A, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore HCF, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-

- Shimon S, Fruscio R, Cui W, Wong SM, **Vernieri C**, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg KA, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalinska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee YJ, Maria C, Azim HA Jr, Boni L, Partridge AH; BRCA BCY Collaboration. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study. *JAMA* 2024. PMID: 38059899
- 26 Crispo A, Augustin LSA, Luongo A, Calderaio C, Breda J, Coluccia S, Calabrese A, Marrazzo V, Giannatiempo R, Trasacco P, Palumbo E, Vitale S, Porciello G, Di Gennaro P, Caputo R, Buono G, **Vernieri C**, Schettini F, Grimaldi M, Nocerino F, Celentano E, Amore A, Giuliano M, De Placido P, De Angelis C, Bianco R, De Laurentiis M, La Vecchia C, Arpino G. Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients. *Sci Rep*. 2023. PMID: 38040773
 - 27 Botticelli A, Caputo R, Scagnoli S, Pisegna S, De Laurentiis M, Curigliano G, Lambertini M, Pantano F, Palazzo A, Paris I, **Vernieri C**, Tedesco B, Giampaglia M, Palleschi M, Ballatore Z, Alesini D, D'Auria G, Fabbri A, Rossi L, Verrazzo A, Scafetta R, Marinelli D, Sposetti C, Barberi V, Strigari L, Marchetti P, Santini D, Fabi A. Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study. *Oncologist* 2024. PMID: 37995313
 - 28 Martelli G, Barretta F, **Vernieri C**, Folli S, Pruneri G, Segattini S, Trapani A, Carolla C, Spatti G, Miceli R, Ferraris C. Prophylactic Salpingo-Oophorectomy and Survival After BRCA1/2 Breast Cancer Resection. *JAMA Surg*. PMID: 37792368
 - 29 Mosconi P, Colombo C, Paletta P, Gangeri L, Pellegrini C, Garralda E, Miceli R, Brunelli C; CEE_DART Consortium. Public and patient involvement: a survey on knowledge, experience and opinions among researchers within a precision oncology European project. *BMC Cancer* 2023. PMID: 37648965
 - 30 Zattarin E, Taglialatela I, Lobefaro R, Leporati R, Fucà G, Ligorio F, Sposetti C, Provenzano L, Azzollini J, Vingiani A, Ferraris C, Martelli G, Manoukian S, Pruneri G, de Braud F, **Vernieri C***. Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities. *Crit Rev Oncol Hematol* 2023. PMID: 37643668
 - 31 Ligorio F, Provenzano L and **Vernieri C***. Fasting-mimicking diet: a metabolic approach for the treatment of breast cancer. *Curr Opin Oncol* 2023. PMID 37621169
 - 32 Ligorio F, Lobefaro R, Fucà G, Provenzano L, Zanenga L, Nasca V, Sposetti C, Salvadori G, Ficchi A, Franza A, Martinetti A, Sottotetti E, Formisano B, Depretto C, Scaperrotta G, Belfiore A, Vingiani A, Ferraris C, Pruneri G, de Braud F and **Vernieri C***. Adding Fasting-Mimicking Diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple negative breast cancer patients: a sub-analysis of the NCT03340935 trial. *Int J Cancer* 2023. PMID: 37615485
 - 33 Vingiani A, Agnelli L, Duca M, Lorenzini D, Damian S, Proto C, Niger M, Nichetti F, Tamborini E, Perrone F, Piccolo A, Manoukian S, Azzollini J, Brambilla M, Colombo E, Lopez S, **Vernieri C**, Marra F, Conca E, Busico A, Capone I, Bozzi F, Angelini M, Devecchi A, Salvatori R, De Micheli V, Baggi A, Pasini S, Jommi C, Ladisa V, Apolone G, De Braud F, Pruneri G. Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care. *JCO Precis Oncol* 2023. PMID: 37487147
 - 34 Valenza C, Trapani S, Trapani D, Gandini S, Sposetti C, Bielo LB, Marra A, Giarratabo T, Favero D, Cortesi L, Moscetti L, Pistelli M, Berardi R, Zambelli A, Lambertini M, Del Mastro L, Guarneri V, **Vernieri C**, Curigliano G. Platinum-based chemotherapy and PARP Inhibitors for patients with a germline BRCA pathogenic variant and advanced

- breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments. *Eur J Cancer* 2023. PMID: 37437366
- 35 Licata L, Viale G, Giuliano M, Curigliano G, Chavez-MacGregor M, Foldi J, Oke O, Collins J, Del Mastro L, Puglisi F, Montemurro F, **Vernieri C**, Gerratana L, Giordano S, Rognone A, Sica L, Gentilini O, Cascinu S, Pusztai L, Giordano A, Criscitiello C, Bianchini G. Oncotype Dx results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer. *NPJ Breast Cancer* 2023. PMID: 37291235
 - 36 Zattarin E, Presti D, Mariani L, Sposetti C, Leporati R, Menichetti A, Corti C, Benvenuti C, Fucà G, Lobefaro R, Ligorio F, Provenzano L, Vingiani A, Del Vecchio M, Griguolo G, Sirico M, Bernocchi O, Marra A, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Esposito A, Giorgi CA, Lalli L, Boldrini L, Giacchetti PPB, Schianca AC, Guarneri V, Pedersini R, Losurdo A, Zambelli A, Generali D, Criscitiello C, Curigliano G, Pruneri G, de Braud F, Dieci MV, **Vernieri C***. Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors. *NPJ Breast Cancer* 2023. PMID: 37069173
 - 37 Provenzano L, Lobefaro R, Ligorio F, Zattarin E, Zambelli L, Sposetti C, Presti D, Montelatici G, Ficchi A, Martinetti A, Arata A, Del Vecchio M, Lauria Pantano C, Formisano B, Bianchi GV, Capri G, de Braud F, **Vernieri C**, Fucà G. The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis. *Ther Adv Med Oncol* 2023. PMID: 37063779
 - 38 Lobefaro R, Mariani L, Peverelli G, Ligorio F, Fucà G, Rametta A, Zattarin E, Leporati R, Presti D, Cantarelli B, Depretto C, Vingiani A, Manoukian S, Scaperrotta G, Bianchi GV, Capri G, Pruneri G, de Braud F, **Vernieri C***. Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison. *Clin Breast Cancer* 2023. PMID: 36599769
 - 39 Ferrando L, Vingiani A, Garuti A, **Vernieri C**, Belfiore A, Agnelli L, Dagrada G, Ivanoiu D, Bonizzi G, Munzone E, Lippolis L, Dameri M, Ravera F, Colleoni M, Viale G, Magnani L, Ballestrero A, Zoppoli G, Pruneri G. ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). *PLoS Genet.* 2023. PMID: 36595552
 - 40 Di Cosimo S, La Rocca E, Ljevar S, De Santis MC, Bini M, Cappelletti V, Valenti M, Baili P, de Braud FG, Folli S, Scaperrotta G, Volpi C, Vingiani A, **Vernieri C**, Verderio P, Miceli R, Pruneri G. Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world. *Front Mol Biosci.* 2022. PMID: 36225259
 - 41 Zattarin E, Nichetti F, Ligorio F, Mazzeo L, Lobefaro R, Fucà G, Peverelli G, Vingiani A, Bianchi GV, Capri G, de Braud F, **Vernieri C***. Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin. *Front Oncol* 2022. PMID: 36059635
 - 42 Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal MA, Corsetto PA, Belfiore A, Lorenzini D, Daidone MG, Vingiani A, Gianni L, Pupa SM, Bianchini G, Pruneri G, **Vernieri C***. Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab. *J Natl Cancer Inst.* 2022. PMID: 358789270
 - 43 Ligorio F, Fucà G, Provenzano L, Lobefaro R, Zanenga L, Vingiani A, Belfiore A, Lorenzoni A, Alessi A, Pruneri G, de Braud F, **Vernieri C***. Exceptional tumor responses

- to fasting-mimicking diet combined with standard anticancer therapies: a sub-analysis of the NCT03340935 trial. *Eur J Cancer* 2022. PMID: 35810555
- 44 Green BJ, Marazzini M, Hershey B, Fardin A, Li Q, Wang Z, Giangreco G, Pisati F, Marchesi S, Disanza A, Frittoli E, Martini E, Magni S, Beznoussenko GV, **Vernieri C**, Lobefaro R, Parazzoli D, Maiuri P, Havas K, Labib M, Sigismund S, Fiore PPD, Gunby RH, Kelley SO, Scita G. PillarX: A Microfluidic Device to Profile Circulating Tumor Cell Clusters Based on Geometry, Deformability, and Epithelial State. *Small* 2022. PMID 35344274
 - 45 Ligorio F, Zambelli L, Fucà, Lobefaro R, Santamaria M, Zattarin E, de Braud F, **Vernieri C***. Prognostic Impact of Body Mass Index (BMI) in HER2-positive Breast Cancer Treated with Anti-HER2 Therapies: from preclinical rationale to clinical implications. *Ther Adv Med Oncol* 2022; 14:17588359221079123. PMID: 35281350
 - 46 Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, Razzak A, Braña I, De Petris L, Yachnin J, Baird RD, Lorient Y, Massard C, Martin-Romano P, Opdam F, Schlenk RF, **Vernieri C**, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium, Balmaña J, Apolone G, Caldas C, Bergh J, Ernberg I, Fröhling S, Garralda E, Karlsson C, Tabernero J, Voest E, Rodon J, Lehtiö J. *Nat Cancer*. 2022;3(2):251-261. PMID: 35221333
 - 47 Pusceddu S, **Vernieri C**, Di Maio M, Prinzi N, Torchio M, Corti F, Coppa J, Buzzoni R, Di Bartolomeo M, Milione M, Regnault B, Truong Thanh XM, Mazzaferro V, de Braud F. Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study. *Cancers (Basel)*. 2021;14(1):69. PMID: 35008233
 - 48 **Vernieri C***, Fucà G, Ligorio F, Huber V, Vingiani A, Iannelli F, Raimondi A, Rinchai D, Frigè G, Belfiore A, Lalli L, Chiodoni C, Cancila V, Zanardi F, Ajazi A, Cortellino S, Vallacchi V, Squarcina P, Cova A, Pesce S, Frati P, Mall R, Corsetto PA, Rizzo AM, Ferraris C, Folli S, Garassino MC, Capri G, Bianchi G, Colombo MP, Minucci S, Foiani M, Longo VD, Apolone G, Torri V, Pruner G, Bedognetti D, Rivoltini L, de Braud F. Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in cancer patients. *Cancer Discov*. 2022;12(1):90-107. PMID: 34789537
 - 49 Salvadori G, Zanardi F, Iannelli F, Lobefaro R, **Vernieri C**, Longo VD. Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape. *Cell Metab*. 2021;33(11):2247-2259. PMID: 34731655.
 - 50 Pupa SM, Ligorio F, Cancila V, Franceschini A, Tripodo C, **Vernieri C**, Castagnoli L. HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness. *Cancers (Basel)*. 2021;13(19):4778. PMID: 34638263.
 - 51 Ajazi A, Bruhn C, Shubassi G, Lucca C, Ferrari E, Cattaneo A, Bachi A, Manfrini N, Biffo S, Martini E, Minucci S, **Vernieri C**, Foiani M. Endosomal trafficking and DNA damage checkpoint kinases dictate survival to replication stress by regulating amino acid uptake and protein synthesis. *Dev Cell* 2021;56(18):2607-2622. PMID: 34534458.
 - 52 Valdemarin F, Caffa I, Persia A, Cremonini AL, Ferrando L, Tagliafico L, Tagliafico A, Guijarro A, Carbone F, Ministrini S, Bertolotto M, Becherini P, Bonfiglio T, Giannotti C, Khalifa A, Ghanem M, Cea M, Sucameli M, Murialdo R, Barbero V, Gradaschi R, Bruzzone F, Borgarelli C, Lambertini M, **Vernieri C**, et al. Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment. *Cancers (Basel)*. 2021;13(16):4013. PMID: 34439167.

- 53 Dameri M, Ferrando L, Cirmena G, **Vernieri C**, Pruneri G, Ballestrero A, Zoppoli G. Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer. *Int J Mol Sci.* 2021;22(13):7154. PMID: 34281208.
- 54 Ligorio F, Fucà G, Zattarin E, Lobefaro R, Zambelli L, Leporati R, Rea C, Mariani G, Bianchi GV, Capri G, de Braud F, **Vernieri C***. The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab. *Cancers (Basel).* 2021;13(8):1964.
- 55 Ligorio F, Pellegrini I, Castagnoli L, Vingiani A, Lobefaro R, Zattarin E, Santamaria M, Pupa SM, Pruneri G, de Braud F, **Vernieri C***. Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. *Cancer Lett.* 2021;511:77-87. PMID: 33961924.
- 56 **Vernieri C***, Nichetti F, Lalli L, Moscetti L, Giorgi CA, Griguolo G, Marra A, Randon G, Rea CG, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A, Agostinetto E, Bernocchi O, Catania G, Vantaggiato A, Palleschi M, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, Lo Vullo S, Gerratana L, Puglisi F, La Verde N, Arpino G, Rocca A, Ciccarese M, Pedersini R, Fabi A, Generali D, Losurdo A, Montemurro F, Curigliano G, Del Mastro L, Michelotti A, Cortesi E, Guarneri V, Pruneri G, Mariani L, de Braud F. Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer: the EVERMET study. *Clin Cancer Res.* 2021. PMID: 33785482
- 57 Ligorio F, Zambelli L, Bottiglieri A, Castagnoli L, Zattarin E, Lobefaro R, Ottini A, Vingiani A, Pupa S.M., Bianchi, G.V., Capri G, Pruneri G, de Braud F, **Vernieri C***. Hormone receptor status influences the impact of Body Mass Index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. *Ther Adv Med Oncol.* 2021;13:17588359211006960. PMID: 33948122
- 58 Lobefaro R, Zattarin E, Nichetti F, Prisciandaro M, Ligorio F, Brambilla M, Sepe P, Corti F, Peverelli G, Ottini A, Beninato T, Mazzeo L, Rea C.G, Mariani G, de Braud F, Bianchi GV, **Vernieri C***, Capri G. Antitumor activity and efficacy of shorter vs. longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a ten-year, retrospective analysis. *Ther Adv Med Oncol.* 2020;12:1758835920970081. PMID: 33335565
- 59 Zattarin E, Leporati R, Ligorio F, Lobefaro R, Vingiani A, Pruneri G, **Vernieri C***. Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings and Therapeutic Implications. *Cells* 2020; 9(12), 2644. PMID: 33316954
- 60 Borzi C, Galli G, Ganzinelli M, Signorelli D, **Vernieri C**, Garassino MC, Sozzi G, Moro M. Beyond *LKB1* Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment. *Pharmaceuticals (Basel).* 2020;13(11):385. PMID: 33202760
- 61 Sirico M, Bernocchi O, Sobhani N, Giudici F, Corona SP, **Vernieri C**, et al. Early Changes of the Standardized Uptake Values (SUV_{max}) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. *Cancers (Basel)* 2020;12(11):3314. PMID: 33182575
- 62 Borreani C, Alfieri S, Infante G, Miceli R, Mariani P, Bosisio M, **Vernieri C**, Bianchi GV, Capri G. Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters. *Oncology.* 2020;1-12. PMID: 32992318
- 63 **Vernieri C***, Ligorio F, Zattarin E, Rivoltini L, de Braud F. Fasting-mimicking diet plus chemotherapy in breast cancer treatment. *Nat Commun.* 2020;11(1):4274. PMID: 32848145

- 64 Pusceddu S, **Vernieri C**, et al. The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. *Therap Adv Gastroenterol*. 2020;13:1756284820927271. PMID: 32821286
- 65 Caffa I, Spagnolo V, **Vernieri C**, et al. Fasting-mimicking diet and hormone therapy induce breast cancer regression. *Nature* 2020;583(7817):620-624. PMID: 32669709
- 66 Tamborero D, Dienstmann R, Rachid MH, Boekel J, Baird R, Braña I, De Petris L, Yachnin J, Massard C, Opdam FL, Schlenk R, **Vernieri C**, et al. Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. *Nat Med*. 2020;26(7):992-994. PMID: 32632195
- 67 D'Amico S, Krasnowska EK, Manni I, Toietta G, Baldari S, Piaggio G, Ranalli M, Gambacurta A, **Vernieri C**, et al. DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. *Cells* 2020;9(5):1260. PMID: 32438775
- 68 **Vernieri C**[#], Ganzinelli M, Rulli E, et al. *LKB1* mutations are not associated with the efficacy of first- and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. *ESMO Open* 2020;5(3):e000748. PMID: 32467099
- 69 Di Tano M, Raucci F, **Vernieri C**, et al. Synergistic effect of Fasting-mimicking diet and vitamin C against *KRAS* mutated cancers. *Nat Commun*. 2020;11(1):2332. PMID: 32393788
- 70 Mirabile A, Rivoltini L, Daveri E, **Vernieri C**, et al. Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. *Cancers (Basel)* 2020; 12(5). PMID: 32375310
- 71 Zattarin E and **Vernieri C**^{*}. Sarcopenia and monocyte-to-lymphocyte ratio as prognostic factors in early-stage breast cancer. *Ann Transl Med*. 2020;8(12):737. PMID: 32647662
- 72 **Vernieri C**[#], Corti F, Nichetti F, et al. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeding different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. *Breast Cancer Res*. 2020;22(1):33. PMID 3225811
- 73 **Vernieri C**[#], Prisciandaro M, Nichetti F, et al. Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breat Cancer. *Cancers (Basel)*. 2020;12(3). PMID 32155941
- 74 Castagnoli L, De Santis F, Volpari T, **Vernieri C**, at al. Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure. *Cells*. 2020;9(3). PMID 32120774
- 75 Kong WJ, **Vernieri C**, Foiani M, Jiang JD. Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders. *Pharmacol Ther*. 2020 May;209:107496. PMID: 32001311
- 76 **Vernieri C**[#], Pusceddu S, de Braud F. Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors. *Front Oncol* 2019;9:902
- 77 Fucà G, Mariani L, Lo Vullo S, Galli G, Berardi R, Di Nicola M, **Vernieri C** et al. Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study. *Sci Rep* 2019;9(1):12993. PMID: 31506579
- 78 Koschorke A, Faraci S, Giani D, Chiodoni C, Iorio E, Canese R, Colombo MP, Lamolinara A, Iezzi M, Ladomery M, **Vernieri C**, et al. Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. *Cell Oncol (Dordr)* 2019. PMID: 31376137

- 79 Rivoltini L, **Vernieri C**, Huber V. The *AURORA* of a New Way to Value Myeloid Immunosuppression in Cancer. *Cancer Res.* 2019;79(13):3169-3171. PMID: 31262832
- 80 **Vernieri C**[#], Milano M, Brambilla M, et al. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research directions and therapeutic perspectives. *Crit Rev Oncol Hematol* 2019;139:53-66. PMID: 31112882
- 81 Corno A, Chiroli E, Gross F, **Vernieri C**, et al. Cellular response upon proliferation in the presence of an active mitotic checkpoint. *Life Science Alliance* 2019;2(3). PMID: 31068378
- 82 Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, **Vernieri C**, et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. *ESMO Open* 2019;4(1). PMID: 30964126
- 83 Cona MS, Lecchi M, Cresta S, Damian S, Del Vecchio M, Necchi A, Poggi MM, Raggi D, Randon G, Ratta R, Signorelli D, **Vernieri C**, et al. Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. *Cancers (Basel)* 2019 Feb 14;1(2). PMID: 30769874
- 84 **Vernieri C**[#], Prisciandaro M, Milano M, et al. Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. *Clin Breast Cancer* 2019;19(2):e306-e318. PMID: 30635175
- 85 **Vernieri C**[#], Signorelli D, Galli G, et al. Exploiting Fasting-mimicking Diet and METformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. *Clin Lung Cancer* 2019;20(3):e413-e417. PMID 30617039
- 86 **Vernieri C**[#], Galli F, Ferrari L, et al. Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. *Oncologist* 2019;24(3):385-393. PMID: 30606884
- 87 **Vernieri C**[#], Pusceddu S, Fucà G, et al. Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). *Int J Cancer* 2019;144(7):1704-1712. PMID: 30520016
- 88 De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Di Cosimo S, Franceschini D, Fucà G, Hiscott J, Malmberg KJ, McGranahan N, Pietrantonio F, Rivoltini L, Sangaletti S, Tagliabue E, Tripodo C, **Vernieri C**, Zitvogel L, Pupa SM, Di Nicola M. Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eight annual meeting. *Cytokine Growth Factor Rev* 2018;44:1-10
- 89 Moro M, Caiola E, Ganzinelli M, Zulato E, Rulli E, Marabese M, Centonze G, Busico A, Pastorino U, de Braud FG, **Vernieri C**, et al. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. *J Thorac Oncol* 2018;13(11):1692-1704. PMID: 30149143
- 90 Castagnoli L, Iorio E, Dugo M, Koschorke A, Faraci S, Canese R, Casalini P, Nanni P, **Vernieri C**, et al. Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer. *J Cell Physiol* 2019; 234(2):1768-1779. PMID: 30132876
- 91 Brighi N, La Rosa S, Rossi G, Grillo F, Pusceddu S, Rinzivillo M, Spada F, Tafuto S, Massironi S, Faggiano A, Antonuzzo L, Santini D, Sessa F, Maragliano R, Gelsomino F, Albertelli M, **Vernieri C**, Panzuto F, Fazio N, De Divitiis C, Lamberti G, Colao A, Fave GD, Campana D. Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study. *Ann Surg.* 2018 Jul 10. PMID: 29995678

- 92 **Vernieri C^{*,#}**, Mennitto A, Prisciandaro M. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. *Sci Rep*. 2018 Jun 7;8(1):8703. PMID: 29880896
- 93 Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Cartenì G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregni M, Massari F, Buti S, De Giorgi U, Zustovich F, Milella M, Calabrò F, Mancini ML, Tortora G, **Vernieri C** et al. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. *Clin Genitourin Cancer*. 2018 Apr 19. pii: S1558-7673(18)30084-3. PMID: 29753637
- 94 Pusceddu S, **Vernieri C** et al. Metformin Use Associates With Longer Progression-free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. *Gastroenterology* 2018;155(2):479-489. PMID: 29655834
- 95 Pusceddu S, Barretta F, Trama A, Botta L, Milione M et al. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. *Endocr Relat Cancer*. 2018 Jun;25(6):607-618. PMID: 29559553
- 96 **Vernieri C^{*,#}**, Nichetti F et al. Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives. *Crit Rev Oncol Hematol*. 2018 Mar;123:57-73. PMID: 29482780
- 97 Bonaiuti P, Chiroli E, Gross F, Corno A, **Vernieri C** et al. Cells Escape an Operational Mitotic Checkpoint through a Stochastic Process. *Curr Biol*. 2018 Jan 8;28(1):28-37.e7. PMID: 29249657
- 98 Oddo D, Siravegna G, Gloghini A, **Vernieri C** et al. Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. *Br J Cancer*. 2017 Jul 25;117(3):347-352. PMID: 28654634
- 99 **Vernieri C^{*,#}**, Milano M, Mennitto A et al. Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, moncentric, retrospective study. *Breast Cancer Res Treat*. 2017 Sep;165(2):365-373. PMID: 28616768
- 100 Pusceddu S, Prinzi N, Lo Russo G, Femia D, Milione M, Perrone F, Tamborini E, Concas L, Pulice I, **Vernieri C**, Corti F, Buzzoni R, de Braud F. Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. *Future Oncol*. 2017 Aug;13(19):1677-1683. PMID: 28580793
- 101 Pusceddu S, Verzoni E, Prinzi N, Mennitto A, Femia D, Grassi P, Concas L, **Vernieri C**, Lo Russo G, Procopio G. Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. *Ther Adv Med Oncol*. 2017 Mar;9(3):183-188. PMID: 28344663
- 102 **Vernieri C^{*,#}**, Casola S, Foiani M, et al: Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. *Cancer Discovery* 2016;6(12):1315-1333. PMID: 27872127
- 103 Mennitto A, **Vernieri C** and Procopio G. Urachal carcinoma: towards a precision medicine. *Translational Cancer research* 2016; Vol 5, Supplement 7.
- 104 Pietrantonio F, **Vernieri C**, Siravegna G, et al: Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer. *Clin Cancer Res* 2017;23(10):2414-2422. PMID: 27780856
- 105 **Vernieri C[#]**, Femia D, Pusceddu S, et al: Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up. *Case reports in oncology* 9:432-439, (2016). PMID: 27721764
- 106 Pusceddu S, Femia D, Lo Russo G, Ortolani S, Milione M, Maccauro M, **Vernieri C** et al: Update on medical treatment of small intestinal neuroendocrine tumors. *Expert review of anticancer therapy* 2016;16:969-76. PMID: 27353232

- 107 Pusceddu, S., de Braud, F., Lo Russo, G., Concas, L., Femia, D., **Vernieri, C.** et al. How do results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. *Oncotarget* 2016;7(28):44841-44847. PMID: 27057638
- 108 Pusceddu, S., Buzzoni, R., **Vernieri, C.** et al. Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. *Future Oncol* 2016;12(10):1251-60. PMID:26890290
- 109 Crespo, C. L., **Vernieri, C.** et al. The PAR complex controls the spatiotemporal dynamics of F-actin and the MTOC in directionally migrating leukocytes. *J Cell Sci* 2014;127:4381-4395. PMID: 25179599
- 110 **Vernieri, C[#]**, Chiroli, E., Francia, V., Gross, F. & Ciliberto, A. Adaptation to the spindle checkpoint is regulated by the interplay between Cdc28/Clbs and PP2ACdc55. *J Cell Biol* 2013;202, 765-778. PMID: 23999167
- 111 Santaguida S, **Vernieri C**, Villa F, Ciliberto A, Musacchio A. Evidence that Aurora B is implicated in spindle checkpoint signaling independently or error correction. *EMBO J*. 2011 Apr 20;30(8):1508- 19. PMID: 21407176

* **Corresponding author**

First-co-first author

H-index (Scopus: <https://www.scopus.com/authid/detail.uri?authorId=42962495400>): **30**

ORAL COMMUNICATIONS AT CONFERENCES

05.07.2025: 21th International Fasting Congress (Berlin, Germany). Invited Speaker for a talk entitled: “Fasting in Immunotherapy”

04.07.2025: Scientific Symposium on Fasting Research (Berlin, Germany). Invited speaker for a talk entitled: “Workshop Fasting and Oncology: Harmonization of Clinical Practice”

26.06.2025: Optimal shared management in patients with HR+ HER2- BC (Milan, Italy). Scientific chair

5.5.2025: 3rd Milan “Me(e)t immune Conference - how metabolism meets the immune system in human malignancies” (Milan, Italy). Scientific chair.

11.4.2025: HER Challenge meeting (Bergamo, Italy). Scientific chair.

7.4.2025: B.I.T. Breast In Translation 2.0 International congress (Padova, Italy). Scientific chair.

25.3.2025: Scientific chair of the meeting “abBRaCciAmi: abbracciare la comunicazione e la cura dei tumori legati a BRCA” (Milan, Italy).

10.11.2024: Annual Meeting of the “Associazione Italiana di Oncologia Medica” (AIOM). Oral communication with a presentation entitled: “Effectiveness of first-line palbociclib, ribociclib and abemaciclib in patients with HR+/HER2- aBC: real-world comparison from the multicenter, Italian study PALMARES-2”.

24.10.2024: “20th MEET THE PROFESSOR: Advanced International Breast Cancer Course (AIBCC)” meeting (Padua, Italy). Awardee lecture entitled “Boosting Academic Research to Meet the Unmet Needs in Breast Cancer Therapy”. Invited speaker for a presentation entitled “HR+ disease: current algorithm”

11.10.2024: “2024 CARCINOMA MAMMARIO METASTATICO: QUALI NOVITÀ?” meeting organized by AIGOM (Associazione Italiana Gruppi Oncologici Multidisciplinari)

(Rome, Italy). Invited speaker for a presentation entitled “Fasting-mimicking diet and metformin: the BREAKFAST trial”.

26.09.2024: “64th Annual Meeting of the Italian Cancer Society” (SIC) (Milan, Italy). Invited speaker for a presentation entitled: “The role of amino acids in cancer progression and response to treatment”

09.09.2024: “DONNA E CANCRO IV Edizione: From bench to bedside” meeting (Milan, Italy). Invited speaker for a presentation entitled: “Neoplasia luminale: nuovi biomarcatori ed algoritmi terapeutici”.

08.09.2024: “46th ESPEN Congress on Clinical Nutrition and Metabolism” (Milan, Italy). Invited speaker for a presentation entitled: “Immune response modulation by nutrition”.

05.09.2024: “INTERNATIONAL SUMMER SCHOOL ON MOLECULAR ONCOLOGY: 4th Edition” (Verbania, Italy). Invited speaker for a presentation entitled: “Fasting-Mimicking diet and cancer metabolism”

30.08.2024: 33rd BioCity Symposium “Unleashing the power of metabolism” (Turku, Finland). Invited speaker for a presentation entitled: “Targeted metabolic interventions in cancer therapy”.

3.6.2024: 2024 ASCO (American Society of Clinical Oncology): Annual Meeting (Chicago, Illinois, U.S.). Oral presentation: “Comparison of antitumor efficacy of first-line Palbociclib, Ribociclib or Abemaciclib in patients with HR+/HER2- aBC: results of the multicenter, real-world, Italian study PALMARES-2”.

31.05.2024: EMBO Workshop “The many faces of cancer evolution” (Rimini, Italy). Invited speaker for a presentation entitled “Optimizing the balance between metabolite restriction and supplementation in cancer therapy”.

3.5.2024: 2nd Milan ME[E]T IMMUNE Conference: How Metabolism Meets the Immune System in Human Malignancies. Scientific Committee and speaker with a presentation entitled: “Balancing metabolite restriction and supplementation in triple-negative breast cancer metabolism”

29.4.2024: B.I.T.: Breast In Translation International meeting (Padova, Italy). Scientific co-chair.

26.4.2024: 4th Protein Calorie Restriction Workshop (Kocaeli, Turkey). Invited speaker for a presentation entitled: “Nutritional and pharmacologic metabolic interventions to reprogram cancer metabolism: from preclinical to clinical evidence”.

22.4.2024: AIRC for Young Scientists conference (IFOM, Milan, Italy). Invited speaker for a presentation entitled: “Targeting amino acid metabolism to boost the anticancer activity of calorie restriction”

08.02.2024: “Clinical Nutrition Pills” congress (Cesena). Invited speaker for a talk entitled: “Role of fasting in cancer patients”

05.02.2024: Cancer Core Europe Annual Meeting (Milan, Italy). Invited speaker for a talk entitled: “Metabolic reprogramming in solid tumors”

14.12.2023: “Shared Decision Making nel tumore della mammella metastatico” (Naples, Italy). Relatore invitato con una relazione dal titolo: “Revisione della letteratura circa i campi applicativi della SDM”

07.12.2023: San Antonio Breast Cancer Symposium (SABCS 2023) (San Antonio, Texas, U.S.). Oral presentation: “Precocious modulation of metabolic and immunological parameters predicts tumor response to fasting-mimicking diet plus chemotherapy in patients with early stage TNBC”.

13.09.2023: International Summer School on Immuno-Oncology (3rd edition) (Verbania, Italy). Invited speaker for a talk entitled: “Innovative IO in solid tumors: what’s next?”

24.06.2023: 20th International fasting Congress (Berlin, Germany). Invited Speaker for a talk entitled: “Fasting in Oncology”

23.06.2023: Scientific Symposium on Fasting Research (Berlin, Germany). Invited speaker for a talk entitled: “Molecular and Metabolic Mechanisms of Tumor Resistance to Fasting and Fasting Mimicking Diets, from Preclinical to Clinical Studies”

26.05.2023: Novelties from the 18th St. Gallen Breast Cancer Consensus Conference and Focus on Advanced Disease (Bologna, Italy). Invited speaker for a talk entitled: “*Monitoring of disease and risk stratification: Genomics, Transcriptomics and ctDNA*”.

07.05.2023: “Preceptorship Programme on BREAST CANCER: multidisciplinary management, standards of care, therapeutic targets and future perspectives” organized by the European Institute of Oncology (Milan, Italy). Invited Speaker for a talk entitled “*Management of gBRCA carriers in early breast cancer*”.

27.04.2023: “1st ME[E]T IMMUNE CONFERENCE: How Metabolism Meets the Immune System in Human Malignancies” organized by the Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy). Director of the Scientific Committee and speaker for a talk entitled “Severe calorie restriction in breast and lung cancer treatment: past, present and future”.

13.04.2023: Atelier of the Accademia di Senologia “Umberto Veronesi” (Inveruno, Italy). Invited speaker for a talk entitled: “*Multidisciplinary approach in locally advanced disease*”.

12.11.2022: “Preceptorship Programme on BREAST CANCER: multidisciplinary management, standards of care, therapeutic targets and future perspectives” organized by the European Institute of Oncology (Milan, Italy). Invited Speaker for a talk entitled “*Management of gBRCA carriers in early breast cancer*”.

07.10.2022: Conference organized by the Azienda Ospedaliero-Universitaria di Modena, and entitled: “Ottimizzare la scelta della terapia adiuvante nelle neoplasie della mammella: tra linee guida e studi clinici”. Invited speaker for a talk entitled: “*Prognostic and predictive factors in adjuvant therapy: HER2-positive breast cancer*”.

02.10.2022: Annual Meeting of the “Associazione Italiana di Oncologia Medica” (AIOM). Oral communication with a presentation entitled: “*Precocious modulation of peripheral blood lymphocytes predicts long-term outcomes in patients with advanced hormone receptor-positive HER2-negative breast cancer treated with CDK4/6 inhibitors (PALMARES)*”.

12.05.2022: CRICK-MSKCC-IFOM meeting (London), organized by the Francis Crick Institute. Invited speaker for a talk entitled “*Targeting metabolic reprogramming in breast cancer: from molecular mechanisms to clinical trials*”.

01.02.2022: “Biomarkers summit in breast cancer: escalating and de-escalating treatment”. 2nd International Meeting. Virtual meeting organized by IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST S.R.L. Invited Speaker for a talk entitled “*Integrating supportive care: bone health and energy metabolism*”

08.10.2021: “Metabolism-Based Cancer Therapy” (Virtual Symposium organized by Technische Universität Dresden, Germany). Invited Speaker for a talk entitled “*Hypoglycemic diet reshapes systemic metabolism and intratumor immunity in cancer patients*”.

03.12.2020: “KALEIDOSCOPE OF NUTRITIONAL INTERVENTION IN ONCOLOGY” (Virtual event organized by Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy). Invited Speaker for a talk entitled “*Breakfast Project, main results*”.

01.11.2020: Annual Meeting of the “Associazione Italiana di Oncologia Medica” (AIOM) (Virtual Congress). Oral communication with a presentation entitled: “*Blood glucose levels are associated with the efficacy of everolimus-exemestane in patients with advanced HR-positive/HER2-negative breast cancer: the Italian study EVERMET*”.

01.10.2020: “Protein Calorie Restriction Workshop” (International Workshop organized by ETH Zurich and Harvard T.H. Chan School of Public Health) (Virtual Event)). Invited Speaker for a talk entitled “*Metabolic and immunological effects of fasting-mimicking diets in cancer patients*”

28.11.2019: “Learning at the Leaning Tower 2019: GONO Congress on Colorectal Cancer” (Scuola Superiore S. Anna, Pisa, Italy). Invited Speaker. Title of the Presentation: *Discovering tumor cells’ metabolism: a new-old hallmark of cancer.*

15.11.2019: “Breaking Boundaries Metabolism at the Cross-Roads” Conference (IFOM, Milan, Italy). Invited Speaker. Title of the Presentation: *Targeting cancer metabolism: facts, controversies and therapeutic perspectives.*

07.10.2019: Cancer Core Europe Summer School in translational Cancer Research (Albufeira, Portugal). Invited Speaker. Title of the Presentation: *Reprogramming cancer metabolism: current research and potential therapeutic implications.*

27.6.2019: MASTERLUNG (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy). Invited Speaker. Title of the Presentation: *Cellular Metabolism: vulnerabilities and potentially novel combinations.*

09.04.2019: “Protein Calorie Restriction Workshop” (International Workshop organized by Harvard T.H. Chan School of Public Health in Leiden, Netherlands). Invited Speaker for a talk entitled “*Safety and metabolic effects of cyclic calorie restriction in cancer patients: promising findings and potential risks*”

17.11.2018: Annual Meeting of the “Associazione Italiana di Oncologia Medica” (AIOM, Rome, Italy). Invited Speaker in the Educational Session. Title of the Presentation: *Metabolic disruption: a new hallmark of cancer.*

9.11.2018: 1st International Conference on Fasting, Dietary Restriction, Longevity and Disease (Los Angeles, USA). Invited Speaker. Title of the Presentation: *Periodic Fasting and Fasting-Mimicking Diet tin Chemotherapy of Cancers.*

12.10.2018: Conference on “Treatment of metastatic HER2-negative breast cancer” (Rezzato, Italy). Invited speaker. Title of the presentation: *Metabolism and Breast Cancer: Myth or Reality?*

7.10.2018: Cancer Core Europe Summer School in translational Cancer Research (Albufeira, Portugal). Invited Speaker. Title of the Presentation: *Metabolic reprogramming in cancer: current knowledge and potential therapeutic implications.*

25.5.2018: ANDID National Congress (Turin, Italy). Invited Speaker. Title of the Presentation: *Fasting in Oncology.*

26.01.2018: Congress on “Innovative therapy, Monoclonal Antibodies and beyond” (Milan, Italy). Invited speaker. Title of the presentation: *Impact of cyclic fasting mimicking diet (FMD) on cancer patient metabolism.*

17.01.2018: Workshop on Molecular Diagnostics and Innovative Drugs (Trieste, Italy). Invited Speaker. Title of the presentation: *Immunity in Oncology: targets, therapy and nutritional aspects.*

27.05.2017: Nutrition and Longevity Workshop (Genova, Italy). Invited Speaker. Title of the presentation: *The Fasting Mimicking Diet in Cancer Patients: Preliminary Results of the INT 10/17 “Basket” Study.*

26.05.2017: Supportive Care in Oncology: “Systemic Strategy at the Patient Service” (Milan, Italy). Invited Speaker. Title of the Presentation: *Complementary Therapies in Oncology: when and why.*

24.05.2016: 2nd Milan NET Conference. A meeting among active Italian Neuroendocrine Tumor Boards. Presentation of a Clinical Case.

26.6.2013: CHROMO2013: EMBO workshop on Chromosome Segregation and Aneuploidy (Breukelen, The Netherlands). Title of the presentation: *Adaptation to the mitotic checkpoint in budding yeast requires APC/C^{Cdc20} activity and is regulated by the interplay between Cdc28/Clbs and PP2A^{Cdc55}.*

Date: September 22nd 2025

Signature

A handwritten signature in black ink, appearing to be 'C. M.' followed by a horizontal line.